This proposal aims to identify and validate novel circulating protein biomarkers to address critical, unmet needs in cardiovascular disease management. Our studies will specifically focus on myocardial ischemia and early injury, for which no suitable and clinically practical blood biomarkers presently exist. Our goal is to build on our initial observations and working hypotheses that (1) an unbiased proteomics discovery platform will yield novel biomarkers and (2) simultaneous assessment of multiple biomarkers examining different pathophysiological axes will provide complementary information to improve diagnosis and clarify prognosis. Newly developed proteomics techniques, richly-annotated clinical samples, as well as novel biomarkers already identified serve as the underpinnings for the proposed studies:
In Specific Aim 1, we will use our LC-MS/MS-based proteomics platform to identify novel early markers of myocardial injury in three unique cohorts of patients experiencing planned myocardial ischemia or injury: patients undergoing cardiac exercise stress testing with myocardial perfusion imaging, patients subjected to pacing-induced myocardial ischemia in the cardiac catheterization suite, and patients experiencing a planned myocardial infarction for hypertrophic cardiomyopathy.
In Specific Aim 2, we will then characterize novel early markers of myocardial injury in carefully phenotyped cohorts of healthy controls, patients with stable coronary artery disease (CAD), and patients presenting across the spectrum of acute coronary syndromes (ACS).
In Aim 3 a, we will test the hypothesis that the novel biomarkers will aid diagnosis in two currently challenging clinical settings. First, we will test whether measurement of the biomarkers in patients undergoing exercise stress testing will enable the detection of inducible myocardial ischemia. Second, we examine whether measurement of the biomarkers in patients presenting to the Emergency Department with chest pain improves our ability to discriminate between non-ischemic chest pain versus unstable angina.
In Aim 3 b, we will test the hypothesis that the novel biomarkers will offer independent prognostic value beyond traditional clinical risk factors and established biomarkers in patients across several cardiac disease states including initial presentation with unstable angina, recent stabilization after ACS, and stable CAD.

Public Health Relevance

Given the mounting evidence in favor of early treatments for patients presenting with acute coronary artery disease, discovering sensitive and specific biomarkers that provide biochemical evidence of early myocardial injury could have a substantial positive impact on patient care. This project describes the application of new proteomics technology for biomarker discovery and validation of early markers of myocardial injury.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Clinical and Integrative Cardiovascular Sciences Study Section (CICS)
Program Officer
Schwartz, Lisa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Kuhn, Eric; Carr, Steven A (2016) Multiplexed Immunoaffinity Enrichment of Peptides with Anti-peptide Antibodies and Quantification by Stable Isotope Dilution Multiple Reaction Monitoring Mass Spectrometry. Methods Mol Biol 1410:135-67
Svinkina, Tanya; Gu, Hongbo; Silva, Jeffrey C et al. (2015) Deep, Quantitative Coverage of the Lysine Acetylome Using Novel Anti-acetyl-lysine Antibodies and an Optimized Proteomic Workflow. Mol Cell Proteomics 14:2429-40
Keshishian, Hasmik; Burgess, Michael W; Gillette, Michael A et al. (2015) Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury. Mol Cell Proteomics 14:2375-93
Olson, David E; Udeshi, Namrata D; Wolfson, Noah A et al. (2014) An unbiased approach to identify endogenous substrates of ""histone"" deacetylase 8. ACS Chem Biol 9:2210-6
Undheim, Eivind A B; Jones, Alun; Clauser, Karl R et al. (2014) Clawing through evolution: toxin diversification and convergence in the ancient lineage Chilopoda (centipedes). Mol Biol Evol 31:2124-48
Burgess, Michael W; Keshishian, Hasmik; Mani, D R et al. (2014) Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry. Mol Cell Proteomics 13:1137-49
O'Donoghue, Michelle L; Morrow, David A; Tsimikas, Sotirios et al. (2014) Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol 63:520-7
Sharma, Vagisha; Eckels, Josh; Taylor, Greg K et al. (2014) Panorama: a targeted proteomics knowledge base. J Proteome Res 13:4205-10
Bonaca, Marc P; Bhatt, Deepak L; Braunwald, Eugene et al. (2014) Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 167:437-444.e5
Carr, Steven A; Abbatiello, Susan E; Ackermann, Bradley L et al. (2014) Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 13:907-17

Showing the most recent 10 out of 31 publications